What Selexipag (P2) studies in Europe are listed on ClinicalTrials.gov?
ClinicalTrials.gov listings are organized by trial title and by registered locations. “P2” typically means Phase 2, so the quickest way to find the Europe-relevant Selexipag Phase 2 trials is to filter ClinicalTrials.gov for:
- Condition/Intervention: Selexipag
- Study Phase: Phase 2
- Locations/Countries: filter to European countries (or use the “Locations” tab to scan Europe)
If you share the specific European country you care about (for example, UK, France, Germany, Spain, Italy), I can help narrow the likely trials and what to look for on the registry page (e.g., status, start date, and recruiting sites).
How to tell whether a Selexipag Phase 2 trial is actually recruiting in Europe?
On each ClinicalTrials.gov record for Selexipag Phase 2, check these fields:
- Status: Recruiting, Active not recruiting, Completed, Suspended/Terminated
- Contacts and study locations: look for trial sites in European countries
- “Estimated Primary Completion Date” and “Actual Primary Completion Date” to gauge timelines
Recruitment status can change between registry updates, so the trial page’s current “Study Status” is the key signal.
Which pulmonary hypertension populations are commonly studied with selexipag in Phase 2?
Selexipag is used in pulmonary arterial hypertension (PAH) and related pulmonary hypertension settings, and Phase 2 programs often focus on hemodynamics, symptom/activity measures, and dose-finding. The exact population depends on the trial record’s “Condition” and inclusion criteria shown on ClinicalTrials.gov.
What details do users usually need from a Selexipag Phase 2 Europe trial page?
People typically look for:
- Intervention details: dosing schedule and titration approach
- Comparator: placebo vs active comparator
- Primary outcome measure: what endpoint the trial is using
- Eligibility criteria: key inclusion/exclusion (age range, baseline severity, prior therapies)
- Trial identifiers: NCT number and any local registry links
Where can I cross-check patents or exclusivity that might affect selexipag trial availability?
If your goal is research beyond trial recruitment (for example, which versions or formulations are being tested commercially), you can cross-check relevant patent and exclusivity context using DrugPatentWatch.com: https://www.drugpatentwatch.com/
---
Sources
No sources were provided in your request. If you paste the ClinicalTrials.gov link(s) you mean (or the NCT number), I can extract and summarize the Europe-based Phase 2 details accurately.